Rui-Hua Xu

List of Publications by Year
in descending order

370 papers	23,667 citations	10979 71 h-index	11928 134 g-index
384 all docs	384 docs citations	384 times ranked	27262 citing authors

#	Article	IF	Citations
1	Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. Cancer Immunology, Immunotherapy, 2022, 71, 661-674.	2.0	8
2	Effects of preoperative oral carbohydrate administration combined with postoperative early oral intake in elderly patients undergoing hepatectomy with acute-phase inflammation and subjective symptom burden: A prospective randomized controlled study. Asian Journal of Surgery, 2022, 45, 386-395.	0.2	4
3	Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut, 2022, 71, 1340-1349.	6.1	17
4	Association between compliance with enhanced recovery after surgery (ERAS) protocols and postoperative outcome in patients with primary liver cancer undergoing hepatic resection. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3047-3059.	1.2	13
5	Neoadjuvant chemoradiotherapy with or without Pd-1 antibody sintilimab for pMMR/MSS/MSI-L locally advanced rectal cancer: A randomized controlled study (cohort B).. Journal of Clinical Oncology, 2022, 40, TPS210-TPS210.	0.8	1
6	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. Journal of Clinical Oncology, 2022, 40, TPS370-TPS370.	0.8	1
7	Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2â€“ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS365-TPS365.	0.8	5
8	Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduction and Targeted Therapy, 2022, 7, 54.	7.1	84
9	Toripalimab plus chemotherapy in treatment-naÃ¯ve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell, 2022, 40, 277-288.e3.	7.7	177
10	Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Medicine, 2022, 14, 45.	3.6	73
11	Comprehensive profiling of 1015 patientsâ€™ exomes reveals genomic-clinical associations in colorectal cancer. Nature Communications, 2022, 13, 2342.	5.8	21
12	Evaluation of Safety of Treatment With Antiâ€“Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors. JAMA Oncology, 2022, 8, 1042.	3.4	15
13	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel Â± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2022, 28, 3686-3694.	3.2	1
14	Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2022, 40, 11513-11513.	0.8	1
15	Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.. Journal of Clinical Oncology, 2022, 40, 3106-3106.	0.8	2
16	Circulating tumor DNA and recurrence risk in stage II-III gastric cancer.. Journal of Clinical Oncology, 2022, 40, 4054-4054.	0.8	1
17	A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2022, 40, e15543-e15543.	0.8	0
18	Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.. Journal of Clinical Oncology, 2022, 40, LBA4011-LBA4011.	0.8	18

#	Article	IF	Citations
19	LncRNA TMPO-AS1 promotes esophageal squamous cell carcinoma progression by forming biomolecular condensates with FUS and p300 to regulate TMPO transcription. Experimental and Molecular Medicine, 2022, 54, 834-847.	3.2	14
20	Mutational profiles of sporadic synchronous colorectal cancer.. Journal of Clinical Oncology, 2022, 40, e15555-e15555.	0.8	0
21	Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis. Oncogene, 2022, 41, 3912-3924.	2.6	14
22	KIF2C: a novel link between Wnt/Î²-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma. Protein and Cell, 2021, 12, 788-809.	4.8	71
23	3-D RoI-Aware U-Net for Accurate and Efficient Colorectal Tumor Segmentation. IEEE Transactions on Cybernetics, 2021, 51, 5397-5408.	6.2	44
24	Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the <scp>UK Biobank</scp>. International Journal of Cancer, 2021, 148, 1867-1878.	2.3	33
25	Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer. Molecular Therapy, 2021, 29, 587-596.	3.7	52
26	LncRNAâ€mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Communications, 2021, 41, 109-120.	3.7	271
27	Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 490-499.	0.7	5
28	Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterology Report, 2021, 9, 560-570.	0.6	10
29	Correction: Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. Oncotarget, 2021, , .	0.8	0
30	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198899.	1.4	17
31	Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. Journal of Medical Genetics, 2021, , jmedgenet-2020-107230.	1.5	11
32	Primary tumor immune score fails to predict the prognosis of colorectal cancer liver metastases after hepatectomy in Chinese populations. Annals of Translational Medicine, 2021, 9, 310-310.	0.7	5
33	A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. Cancer Medicine, 2021, 10, 1535-1544.	1.3	5
34	Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). Oncologist, 2021, 26, e954-e962.	1.9	14
35	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). Journal of Clinical Oncology, 2021, 39, 704-712.	0.8	156
36	MYC-Activated LncRNA MNX1-AS1 Promotes the Progression of Colorectal Cancer by Stabilizing YB1. Cancer Research, 2021, 81, 2636-2650.	0.4	48

#	Article	IF	Citations
37	The lncRNA XIST/miRâ€125bâ€2â€3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer. Cancer Medicine, 2021, 10, 2423-2441.	1.3	21
38	Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. , 2021, 9, e002114.		10
39	Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform. Engineering, 2021, 7, 526-533.	3.2	5
40	Subgroup analysis by prior anti-VEGFor anti-EGFR target therapy in FRESCO,a randomized, double-blind, Phase IIIÂtrial. Future Oncology, 2021, 17, 1339-1350.	1.1	5
41	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in theÂFRESCO trial. Future Oncology, 2021, 17, 1923-1931.	1.1	2
42	Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.. Journal of Clinical Oncology, 2021, 39, e16022-e16022.	0.8	1
43	Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Annals of Translational Medicine, 2021, 9, 893-893.	0.7	0
44	Performance of common genetic variants in risk prediction for colorectal cancer in Chinese: A two-stage and multicenter study. Genomics, 2021, 113, 867-873.	1.3	1
45	Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine, 2021, 27, 482-500.	3.5	128
46	A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01).. Journal of Clinical Oncology, 2021, 39, e16059-e16059.	0.8	8
47	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. Journal of Clinical Oncology, 2021, 39, TPS4150-TPS4150.	0.8	4
48	Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology, 2021, 14, 80.	6.9	90
49	Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. Oncologist, 2021, 26, e1161-e1170.	1.9	8
50	JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).. Journal of Clinical Oncology, 2021, 39, LBA2-LBA2.	0.8	21
51	ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2021, 39, 4000-4000.	0.8	25
52	DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. Molecular Therapy - Nucleic Acids, 2021, 24, 695-710.	2.3	25
53	Advancing to the era of cancer immunotherapy. Cancer Communications, 2021, 41, 803-829.	3.7	90
54	FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis. Oncogene, 2021, 40, 5168-5181.	2.6	77

#	Article	IF	Citations
55	Cancer incidence, mortality, and burden in China: a timeâ€trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Communications, 2021, 41, 1037-1048.	3.7	358
56	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications, 2021, 41, 747-795.	3.7	323
57	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. OncoTargets and Therapy, 2021, Volume 14, 4439-4450.	1.0	1
58	The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis. Biomolecules, 2021, 11, 1268.	1.8	1
59	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nature Medicine, 2021, 27, 1536-1543.	15.2	197
60	POLE/POLD1 mutation in nonâ€exonuclease domain matters for predicting efficacy of immuneâ€checkpointâ€inhibitor therapy. Clinical and Translational Medicine, 2021, 11, e524.	1.7	6
61	Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma. JAMA - Journal of the American Medical Association, 2021, 326, 916.	3.8	310
62	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Reports Medicine, 2021, 2, 100383.	3.3	49
63	Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study. Investigational New Drugs, 2021, 39, 836-845.	1.2	12
64	Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Theranostics, 2021, 11, 7018-7028.	4.6	37
65	Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 1015-1024.	3.7	32
66	Efficacy and safety of a novel antiâ€HER2 therapeutic antibody RC48 in patients with HER2â€overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a singleâ€arm phase II study. Cancer Communications, 2021, 41, 1173-1182.	3.7	77
67	Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Communications, 2021, 41, 1100-1115.	3.7	71
68	Identification of â€œregulation of RhoA activity panelâ€•as a prognostic and predictive biomarker for gastric cancer. Aging, 2021, 13, 714-734.	1.4	1
69	The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis. Frontiers in Oncology, 2021, 11, 712760.	1.3	14
70	PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. American Journal of Cancer Research, 2021, 11, 5006-5015.	1.4	0
71	Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer. Clinical Epigenetics, 2021, 13, 232.	1.8	17
72	The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Molecular Cancer, 2021, 20, 166.	7.9	60

#	Article	IF	Citations
73	Emerging immunological strategies: recent advances and future directions. Frontiers of Medicine, 2021, 15, 805-828.	1.5	5
74	Prospective observation: Clinical utility of plasma Epsteinâ€“Barr virus DNA load in EBVâ€associated gastric carcinoma patients. International Journal of Cancer, 2020, 146, 272-280.	2.3	41
75	AMPKÎ±1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Oncogene, 2020, 39, 637-650.	2.6	16
76	Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 391-398.	1.4	17
77	Artificial intelligence applications in upper gastrointestinal cancers â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e5.	5.1	0
78	Phase III randomized, placeboâ€controlled, doubleâ€blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatinâ€induced peripheral neurotoxicity in stage II/III colorectal cancer. Cancer Medicine, 2020, 9, 151-159.	1.3	18
79	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <scp>CONCUR</scp> trial. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1307-1316.	1.4	8
80	Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. Cancer Letters, 2020, 473, 74-89.	3.2	63
81	Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells. Theranostics, 2020, 10, 498-515.	4.6	68
82	Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science Translational Medicine, 2020, 12, .	5.8	260
83	NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduction and Targeted Therapy, 2020, 5, 231.	7.1	194
84	Systematic analysis of the transcriptome in smallâ€cell carcinoma of the oesophagus reveals its immune microenvironment. Clinical and Translational Immunology, 2020, 9, e1173.	1.7	2
85	p.P476S mutation of RBPJL inhibits the efficacy of antiâ€PDâ€1 therapy in oesophageal squamous cell carcinoma by blunting Tâ€cell responses. Clinical and Translational Immunology, 2020, 9, e1172.	1.7	1
86	Observational cohort study of clinical outcome in Epsteinâ€“Barr virus associated gastric cancer patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093743.	1.4	16
87	Practical considerations in the use of regorafenib in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095686.	1.4	16
88	Evaluation of a wearable wireless device with artificial intelligence, iThermonitor WT705, for continuous temperature monitoring for patients in surgical wards: a prospective comparative study. BMJ Open, 2020, 10, e039474.	0.8	14
89	Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study. The Lancet Regional Health - Western Pacific, 2020, 4, 100054.	1.3	3
90	Multiparametric MRI and Whole Slide Image-Based Pretreatment Prediction of Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Multicenter Radiopathomic Study. Annals of Surgical Oncology, 2020, 27, 4296-4306.	0.7	37

#	Article	IF	Citations
91	The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Molecular Cancer, 2020, 19, 154.	7.9	64
92	Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Cancer Communications, 2020, 40, 620-632.	3.7	7
93	MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and panâ€cancer. Clinical and Translational Medicine, 2020, 10, e155.	1.7	80
94	Expert opinions on immunotherapy for patients with colorectal cancer. Cancer Communications, 2020, 40, 467-472.	3.7	18
95	VDRâ€“SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduction and Targeted Therapy, 2020, 5, 183.	7.1	30
96	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the PhaseÂ3 FRESCO Trial. Advances in Therapy, 2020, 37, 4585-4598.	1.3	8
97	Relationship between prediagnostic body mass index trajectory and colorectal adenomas: an analysis of the PLCO cancer screening trial. Annals of Translational Medicine, 2020, 8, 815-815.	0.7	0
98	Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients. Frontiers in Oncology, 2020, 10, 563407.	1.3	5
99	Circular RNA: metabolism, functions and interactions with proteins. Molecular Cancer, 2020, 19, 172.	7.9	526
100	PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. Journal of Translational Medicine, 2020, 18, 475.	1.8	23
101	Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis. World Journal of Surgical Oncology, 2020, 18, 98.	0.8	2
102	Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. Clinical and Translational Medicine, 2020, 10, 353-362.	1.7	13
103	ASO Author Reflections: Radiopathomics Strategy of Combing Multi-scale Tumor Information on Pretreatment to Predict the Pathologic Response to Neoadjuvant Therapy. Annals of Surgical Oncology, 2020, 27, 4307-4308.	0.7	2
104	METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway. Frontiers in Oncology, 2020, 10, 115.	1.3	76
105	CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17. Molecular Cancer, 2020, 19, 60.	7.9	110
106	Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nature Communications, 2020, 11, 1507.	5.8	121
107	Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomesâ€”Reply. JAMA Oncology, 2020, 6, 590.	3.4	3
108	Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy. Cancer Immunology, Immunotherapy, 2020, 69, 2623-2634.	2.0	21

#	Article	IF	Citations
109	The drug treatment research of gastrointestinal cancer in China. European Journal of Surgical Oncology, 2020, 46, e3-e6.	0.5	5
110	A phase I study of toripalimab, an antiâ€PDâ€1 antibody, in patients with refractory malignant solid tumors. Cancer Communications, 2020, 40, 345-354.	3.7	30
111	Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer. IScience, 2020, 23, 101302.	1.9	128
112	Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. BMC Cancer, 2020, 20, 131.	1.1	25
113	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). European Journal of Surgical Oncology, 2020, 46, 955-966.	0.5	22
114	A Feedback Circuitry between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis. Cancer Research, 2020, 80, 675-688.	0.4	25
115	Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. Journal of Cancer, 2020, 11, 1063-1074.	1.2	12
116	Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China. Journal of Medical Economics, 2020, 23, 456-463.	1.0	23
117	The Role of Maintenance Therapy in Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, 937.	3.4	1
118	PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. OncoImmunology, 2020, 9, 1711650.	2.1	37
119	Clinical response and biomarker analysis of POLARIS-02 a phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2020, 38, 6542-6542.	0.8	1
120	Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors.. Journal of Clinical Oncology, 2020, 38, e15083-e15083.	0.8	7
121	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. Cancer Biology and Medicine, 2020, 17, 896-909.	1.4	35
122	Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 403-407.	0.7	10
123	Study on Big Data-Supported Clinical Oncology. , 2020, , 325-349.		0
124	Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. American Journal of Cancer Research, 2020, 10, 2946-2954.	1.4	7
125	Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. American Journal of Cancer Research, 2020, 10, 3037-3046.	1.4	0
126	A Coiledâ€Coil Domain Containing 50 Splice Variant Is Modulated by Serine/Arginineâ€Rich Splicing Factor 3 and Promotes Hepatocellular Carcinoma in Mice by the Ras Signaling Pathway. Hepatology, 2019, 69, 179-195.	3.6	67

#	Article	IF	Citations
127	Designing gene panels for tumor mutational burden estimation: the need to shift from â€˜correlationâ€™ to â€˜accuracyâ€™. , 2019, 7, 206.		37
128	Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncology, 2019, 5, 1504.	3.4	287
129	Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism. Cancers, 2019, 11, 931.	1.7	37
130	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2â€positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Communications, 2019, 39, 1-10.	3.7	19
131	N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nature Communications, 2019, 10, 4695.	5.8	418
132	Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. , 2019, 7, 264.		66
133	A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO Molecular Medicine, 2019, 11, e10168.	3.3	90
134	Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting. Journal of Cancer, 2019, 10, 388-396.	1.2	4
135	Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncology, The, 2019, 20, 1645-1654.	5.1	263
136	Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients . Cancer Management and Research, 2019, Volume 11, 3721-3739.	0.9	15
137	A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients . Cancer Management and Research, 2019, Volume 11, 3993-4003.	0.9	4
138	Genome sequencing analysis identifies Epsteinâ€“Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nature Genetics, 2019, 51, 1131-1136.	9.4	133
139	METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma. Molecular Cancer, 2019, 18, 112.	7.9	515
140	Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Annals of Oncology, 2019, 30, 1479-1486.	0.6	336
141	Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer, 2019, 19, 460.	1.1	30
142	The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Communications, 2019, 39, 26.	3.7	26
143	Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 196.	3.5	38
144	Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nature Communications, 2019, 10, 1858.	5.8	242

#	Article	IF	Citations
145	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. JAMA Network Open, 2019, 2, e193433.	2.8	8
146	Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Communications, 2019, 39, 1-12.	3.7	1,177
147	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications, 2019, 39, 1-31.	3.7	418
148	Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis. Theranostics, 2019, 9, 1965-1979.	4.6	168
149	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. Cancer Biology and Medicine, 2019, 16, 189.	1.4	16
150	Correlation between immune signature and highâ€density lipoprotein cholesterol level in stage II/III colorectal cancer. Cancer Medicine, 2019, 8, 1209-1217.	1.3	22
151	Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies. Theranostics, 2019, 9, 1115-1124.	4.6	56
152	IDDF2019-ABS-0245â€…Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. , 2019, , .		0
153	LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer, 2019, 18, 174.	7.9	315
154	The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching. Journal of Cancer, 2019, 10, 602-610.	1.2	10
155	VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients. Chest, 2019, 155, 114-122.	0.4	51
156	qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Research, 2019, 47, D451-D458.	6.5	44
157	Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. Journal of the National Cancer Institute, 2019, 111, 584-596.	3.0	125
158	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. International Journal of Cancer, 2019, 144, 2161-2168.	2.3	34
159	Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut, 2019, 68, 1152-1161.	6.1	118
160	APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. Journal of Clinical Investigation, 2019, 129, 727-743.	3.9	114
161	Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 423-425.	0.7	7
162	Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 805-811.	2.3	18

#	Article	IF	Citations
163	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. Journal of Clinical Oncology, 2019, 37, 711-711.	0.8	0
164	Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside in prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer patients.. Journal of Clinical Oncology, 2019, 37, 674-674.	0.8	0
165	ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis. Cancer Research, 2018, 78, 1972-1985.	0.4	86
166	The genomic landscape of small cell carcinoma of the esophagus. Cell Research, 2018, 28, 771-774.	5.7	23
167	Comparison of survival between rightâ€sided and leftâ€sided colon cancer in different situations. Cancer Medicine, 2018, 7, 1141-1150.	1.3	24
168	Structure of Schlafen13 reveals a new class of tRNA/rRNA- targeting RNase engaged in translational control. Nature Communications, 2018, 9, 1165.	5.8	87
169	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncology, The, 2018, 19, 660-671.	5.1	107
170	Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Letters, 2018, 412, 243-255.	3.2	65
171	SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. Gene, 2018, 640, 43-50.	1.0	19
172	Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis. Stem Cells, 2018, 36, 180-191.	1.4	24
173	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. Journal of Clinical Oncology, 2018, 36, 350-358.	0.8	160
174	A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients. Cell Death Discovery, 2018, 4, 116.	2.0	16
175	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. Journal of Cancer, 2018, 9, 4325-4333.	1.2	16
176	Hypermethylation of APC2 Is a Predictive Epigenetic Biomarker for Chinese Colorectal Cancer. Disease Markers, 2018, 2018, 1-7.	0.6	9
177	The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy. Journal of Cancer, 2018, 9, 3467-3478.	1.2	22
178	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics, 2018, 8, 5213-5230.	4.6	115
179	Phase <scp>II</scp> clinical trial of Sâ€1 plus nanoparticle albuminâ€bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Science, 2018, 109, 3575-3582.	1.7	19
180	Proposal for a New TNM Stage based on the 7th and 8th American Joint Committee on Cancer pTNM Staging Classification for Gastric Cancer. Journal of Cancer, 2018, 9, 3570-3576.	1.2	13

#	Article	IF	Citations
181	Enzymatically synthesized poly(amino-co-ester) polyplexes for systemic delivery of pcDNA-miRNA-214 to suppress colorectal cancer liver metastasis. Journal of Materials Chemistry B, 2018, 6, 6365-6376.	2.9	7
182	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 2486.	3.8	202
183	Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A <scp>SEER</scp>â€based study. Cancer Medicine, 2018, 7, 3662-3672.	1.3	78
184	CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene, 2018, 37, 6025-6040.	2.6	211
185	Editorial announcement regarding title change of Chinese Journal of Cancer to Cancer Communications. Cancer Communications, 2018, 38, 1-1.	3.7	35
186	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. Future Oncology, 2018, 14, 2031-2044.	1.1	20
187	Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation. Theranostics, 2018, 8, 1312-1326.	4.6	46
188	Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy. Journal of Cancer, 2018, 9, 660-666.	1.2	11
189	Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients. Journal of Cancer, 2018, 9, 512-520.	1.2	12
190	The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunology, Immunotherapy, 2018, 67, 435-444.	2.0	61
191	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.. Journal of Clinical Oncology, 2018, 36, 3544-3544.	0.8	1
192	The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 4010-4010.	0.8	19
193	Incidence rate and clinic-pathologic features of EBV-associated gastric carcinoma in China.. Journal of Clinical Oncology, 2018, 36, e16048-e16048.	0.8	0
194	Effect of knockdown of eukaryotic initiation factor 4A2 (eIF4A2) on growth, metastasis, and oxaliplatin sensitivity in colorectal cancer.. Journal of Clinical Oncology, 2018, 36, e15658-e15658.	0.8	0
195	Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.. Journal of Clinical Oncology, 2018, 36, 4045-4045.	0.8	0
196	The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 4735-4743.	0.5	4
197	YAPâ€“IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1643-1648.	3.3	85
198	Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nature Communications, 2017, 8, 14437.	5.8	77

#	Article	IF	Citations
199	Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A largeâ€scale, bigâ€data intelligence platformâ€“based analysis from an endemic area. Cancer, 2017, 123, 3540-3549.	2.0	47
200	Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemotherapy and Pharmacology, 2017, 79, 69-79.	1.1	3
201	Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. International Journal of Cancer, 2017, 141, 152-159.	2.3	38
202	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1637-1651.	5.1	233
203	Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature Materials, 2017, 16, 1155-1161.	13.3	641
204	Genome-wide analysis of Epstein-Barr virus identifies variants and genes associated with gastric carcinoma and population structure. Tumor Biology, 2017, 39, 101042831771419.	0.8	13
205	Long noncoding RNA XIST expedites metastasis and modulates epithelialâ€“mesenchymal transition in colorectal cancer. Cell Death and Disease, 2017, 8, e3011-e3011.	2.7	170
206	Phase <scp>II</scp> study of Sâ€1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. Cancer Science, 2017, 108, 2045-2051.	1.7	7
207	Fibrinogen promotes malignant biological tumor behavior involving epithelialâ€“mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2413-2424.	1.2	52
208	DNA methylation markers for diagnosis and prognosis of common cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7414-7419.	3.3	387
209	Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncology Letters, 2017, 14, 705-714.	0.8	25
210	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology and Oncology, 2017, 10, 22.	6.9	50
211	Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing transâ€arterial chemoembolization therapy. Oncology Letters, 2017, 15, 855-862.	0.8	9
212	Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. Theranostics, 2017, 7, 4836-4849.	4.6	265
213	Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. Journal of Cancer, 2017, 8, 3498-3505.	1.2	11
214	Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer. Journal of Cancer, 2017, 8, 950-958.	1.2	49
215	Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer. Journal of Cancer, 2017, 8, 3531-3537.	1.2	20
216	Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study. BMC Cancer, 2017, 17, 885.	1.1	11

#	Article	IF	Citations
217	Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases. Chinese Journal of Cancer, 2017, 36, 78.	4.9	11
218	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chinese Journal of Cancer, 2017, 36, 97.	4.9	28
219	FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer. OncoTargets and Therapy, 2017, Volume 10, 5065-5076.	1.0	11
220	The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?. Journal of Cancer, 2017, 8, 1179-1186.	1.2	17
221	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology, 2017, 35, 2558-2567.	0.8	98
222	A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO).. Journal of Clinical Oncology, 2017, 35, 3508-3508.	0.8	4
223	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.. Journal of Clinical Oncology, 2017, 35, 128-128.	0.8	7
224	A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).. Journal of Clinical Oncology, 2017, 35, 681-681.	0.8	4
225	Association between lymph node examination and nodal staging for pancreatic adenocarcinoma: A population-based analysis.. Journal of Clinical Oncology, 2017, 35, e15772-e15772.	0.8	0
226	Incidence rate and clinical-pathological features of hereditary diffuse gastric cancer patients in China.. Journal of Clinical Oncology, 2017, 35, 4065-4065.	0.8	0
227	Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. Journal of Cancer, 2016, 7, 694-701.	1.2	10
228	Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications. Theranostics, 2016, 6, 1160-1175.	4.6	75
229	The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy. Medicine (United States), 2016, 95, e3214.	0.4	2
230	Defeating cancer: the 150 most important questions in cancer research and clinical oncology. Chinese Journal of Cancer, 2016, 35, 104.	4.9	13
231	Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. Chinese Journal of Cancer, 2016, 35, 102.	4.9	12
232	Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Letters, 2016, 379, 1-11.	3.2	51
233	Pathological Assessment of the AJCC Tumor Regression Grading System After Preoperative Chemoradiotherapy for Chinese Locally Advanced Rectal Cancer. Medicine (United States), 2016, 95, e2272.	0.4	16
234	Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer. Nanoscale, 2016, 8, 11543-11558.	2.8	53

#	Article	IF	Citations
235	Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factorâ€Î^º<scp>B</scp> activation. Journal of Pineal Research, 2016, 60, 27-38.	3.4	53
236	Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Ecological Management and Restoration, 2016, 30, 1-8.	0.2	15
237	CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma. Cancer Research, 2016, 76, 7277-7289.	0.4	66
238	Impact of marital status on survival of gastric adenocarcinoma patients: Results from the Surveillance Epidemiology and End Results (SEER) Database. Scientific Reports, 2016, 6, 21098.	1.6	32
239	Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. Cell Death and Disease, 2016, 7, e2432-e2432.	2.7	49
240	Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. Journal of Experimental and Clinical Cancer Research, 2016, 35, 142.	3.5	227
241	Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. Chinese Journal of Cancer, 2016, 35, 65.	4.9	22
242	Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine (United States), 2016, 95, e4531.	0.4	14
243	Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. Medical Oncology, 2016, 33, 71.	1.2	12
244	Inhibition of the NF-ÎºB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Letters, 2016, 380, 87-97.	3.2	53
245	Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chinese Journal of Cancer, 2016, 35, 8.	4.9	2
246	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chinese Journal of Cancer, 2016, 35, 13.	4.9	14
247	MGMT in colorectal cancer: a promising component of personalized treatment. Tumor Biology, 2016, 37, 11443-11456.	0.8	11
248	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Journal of Clinical Oncology, 2016, 34, 1448-1454.	0.8	756
249	The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumor Biology, 2016, 37, 1879-1887.	0.8	33
250	Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer, 2016, 19, 234-244.	2.7	90
251	Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget, 2016, 7, 57290-57300.	0.8	23
252	Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget, 2016, 7, 50656-50665.	0.8	39

#	Article	IF	Citations
253	The clinicopathologic relevance and prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapy. Oncotarget, 2016, 7, 75094-75103.	0.8	23
254	Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Oncotarget, 2016, 7, 6335-6344.	0.8	22
255	Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Oncotarget, 2016, 7, 28356-28368.	0.8	16
256	Low preoperative albumin-globulin score predicts favorable survival in esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 30550-30560.	0.8	28
257	Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms. Oncotarget, 2016, 7, 39945-39956.	0.8	13
258	A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Scientific Reports, 2015, 5, 17717.	1.6	21
259	Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy. Medicine (United States), 2015, 94, e1793.	0.4	24
260	Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget, 2015, 6, 38658-38666.	0.8	182
261	Prognostic effect of high pretreatment neutrophil to lymphocyte ratio on survival of patients with gastric adenocarcinoma in China. International Journal of Biological Markers, 2015, 30, 96-103.	0.7	7
262	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 619-629.	5.1	574
263	Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Research and Therapy, 2015, 6, 198.	2.4	40
264	Effect of Raf kinase inhibitor protein expression on malignant biological behavior and progression of colorectal cancer. Oncology Reports, 2015, 34, 2106-2114.	1.2	18
265	Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor Î³ overexpression in human pancreatic carcinoma. International Journal of Oncology, 2015, 46, 175-184.	1.4	8
266	Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. Supportive Care in Cancer, 2015, 23, 1933-1939.	1.0	58
267	Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese Journal of Cancer, 2015, 34, 384-93.	4.9	63
268	The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy. Tumor Biology, 2015, 36, 8213-8219.	0.8	18
269	A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer, 2015, 15, 350.	1.1	126
270	Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Medical Oncology, 2015, 32, 469.	1.2	9

#	Article	IF	Citations
271	Xcâ” inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Letters, 2015, 368, 88-96.	3.2	127
272	Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer, 2015, 18, 168-176.	2.7	209
273	microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. Oncotarget, 2015, 6, 10868-10879.	0.8	64
274	Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: Results from the surveillance epidemiology and end results (SEER) database. Oncotarget, 2015, 6, 33935-33943.	0.8	39
275	S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget, 2015, 6, 35107-35115.	0.8	23
276	Impact of body mass index on survival of esophageal squamous carcinoma patients in southern China. Journal of Thoracic Disease, 2015, 7, 337-45.	0.6	7
277	Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. International Journal of Clinical and Experimental Pathology, 2015, 8, 11084-91.	0.5	66
278	Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World Journal of Gastroenterology, 2014, 20, 264.	1.4	3
279	Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. OncoTargets and Therapy, 2014, 7, 501.	1.0	6
280	Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer, 2014, 14, 823.	1.1	55
281	Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Research, 2014, 16, 434.	2.2	157
282	HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation. International Journal of Cancer, 2014, 134, 2468-2477.	2.3	59
283	Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer. BMC Cancer, 2014, 14, 650.	1.1	19
284	Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma. Annals of Thoracic Surgery, 2014, 97, 1975-1981.	0.7	50
285	Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. Tumor Biology, 2014, 35, 4369-4375.	0.8	23
286	Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal Cancer. Clinical Cancer Research, 2014, 20, 1042-1052.	3.2	120
287	MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer, 2014, 120, 675-682.	2.0	50
288	Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology, 2014, 60, 598-609.	3.6	117

#	Article	IF	Citations
289	Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases. BMC Cancer, 2014, 14, 222.	1.1	15
290	Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANâ€"A Randomized, Phase III Study. Journal of Clinical Oncology, 2014, 32, 2039-2049.	0.8	524
291	Applying chemical bile duct embolization to achieve chemical hepatectomy in hepatolithiasis: aÂfurther experimental study. Journal of Surgical Research, 2014, 187, 113-121.	0.8	9
292	ARRYâ€334543 Reverses Multidrug Resistance by Antagonizing the Activity of ATPâ€Binding Cassette Subfamily G Member 2. Journal of Cellular Biochemistry, 2014, 115, 1381-1391.	1.2	18
293	A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3548-3548.	0.8	4
294	Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer. PLoS ONE, 2014, 9, e89965.	1.1	17
295	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	0.8	41
296	Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. Oncotarget, 2014, 5, 10778-10790.	0.8	48
297	Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World Journal of Gastroenterology, 2014, 20, 3858.	1.4	44
298	Healing time of incision infection after hepatobiliary surgery treated by needle-free incision suture closure. World Journal of Gastroenterology, 2014, 20, 15815.	1.4	2
299	Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World Journal of Gastroenterology, 2014, 20, 18404.	1.4	38
300	The relationship between HER2 expression and Lauren classification in Chinese gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 4065-4065.	0.8	0
301	Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 619-30.	0.5	39
302	The Chinese Journal of Cancer is indexed in Science Citation Index (SCI) expanded. Chinese Journal of Cancer, 2014, 33, 367-8.	4.9	2
303	Retroperitoneal laparoscopic management method of Castleman's disease in the adrenal gland: two cases report and review of the literature. International Journal of Clinical and Experimental Medicine, 2014, 7, 5909-12.	1.3	2
304	Annona squamosa Linn: cytotoxic activity found in leaf extract against human tumor cell lines. Pakistan Journal of Pharmaceutical Sciences, 2014, 27, 1559-63.	0.2	12
305	CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. Journal of Translational Medicine, 2013, 11, 142.	1.8	115
306	Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. Journal of Translational Medicine, 2013, 11, 58.	1.8	142

#	Article	IF	Citations
307	L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. Journal of Hematology and Oncology, 2013, 6, 43.	6.9	52
308	Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1065-1072.	1.1	33
309	The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. Journal of Translational Medicine, 2013, 11, 249.	1.8	34
310	The progress of targeted therapy in advanced gastric cancer. Biomarker Research, 2013, 1, 32.	2.8	33
311	Î²-Phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. Biochemical Pharmacology, 2013, 85, 486-496.	2.0	47
312	Prognostic relevance of <scp>BRD</scp>7 expression in colorectal carcinoma. European Journal of Clinical Investigation, 2013, 43, 131-140.	1.7	41
313	Effective Elimination of Cancer Stem Cells By a Novel Drug Combination Strategy. Stem Cells, 2013, 31, 23-34.	1.4	79
314	Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. Journal of Translational Medicine, 2013, 11, 277.	1.8	35
315	Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis, 2013, 34, 803-811.	1.3	96
316	Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/Î²-Catenin Signaling. PLoS ONE, 2013, 8, e56959.	1.1	37
317	Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma. PLoS ONE, 2013, 8, e63458.	1.1	9
318	Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis. PLoS ONE, 2013, 8, e68974.	1.1	19
319	A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 4025-4025.	0.8	6
320	The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.. Journal of Clinical Oncology, 2013, 31, 4109-4109.	0.8	1
321	MET amplification occurrence and prediction of unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.. Journal of Clinical Oncology, 2013, 31, e15047-e15047.	0.8	1
322	Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy. PLoS ONE, 2013, 8, e53149.	1.1	22
323	S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis. PLoS ONE, 2013, 8, e82798.	1.1	23
324	The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer. PLoS ONE, 2013, 8, e83921.	1.1	27

#	Article	IF	Citations
325	Evaluation of serum HER2 extracellular domain in in metastatic gastric or gastroesophageal junction cancer: Correlation with HER2 status by immunohistochemistry and fluorescence in situ hybridization and clinicopathologic parameters.. Journal of Clinical Oncology, 2013, 31, 4107-4107.	0.8	0
326	High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. European Journal of Cancer Prevention, 2012, 21, 261-267.	0.6	25
327	Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor. Clinical Cancer Research, 2012, 18, 4059-4069.	3.2	129
328	A New Role for PHD in Chemotherapy. Cancer Cell, 2012, 22, 143-144.	7.7	1
329	Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma. Journal of Translational Medicine, 2012, 10, 181.	1.8	19
330	Salvage gemcitabineâ€“vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncology, 2012, 48, 1146-1151.	0.8	27
331	Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Medical Oncology, 2012, 29, 3092-3100.	1.2	187
332	Are Risk Factors Associated with Outcomes in Pancreatic Cancer?. PLoS ONE, 2012, 7, e41984.	1.1	31
333	ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. International Journal of Cancer, 2012, 131, 461-468.	2.3	102
334	Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-Bromopyruvate Propyl Ester. Journal of Bioenergetics and Biomembranes, 2012, 44, 117-125.	1.0	73
335	Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumor Biology, 2012, 33, 749-756.	0.8	101
336	Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. Journal of Translational Medicine, 2012, 10, 16.	1.8	63
337	Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). Journal of Translational Medicine, 2012, 10, 21.	1.8	47
338	The Tumor-Log Odds of Positive Lymph Nodes-Metastasis Staging System, a Promising New Staging System for Gastric Cancer after D2 Resection in China. PLoS ONE, 2012, 7, e31736.	1.1	57
339	The Impact of Glucocorticoids for Cirrhosis Patients Performed Major Liver Resection: A Retrospective Control Study. Hepato-Gastroenterology, 2012, 59, 1220-4.	0.5	0
340	Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chinese Journal of Cancer, 2011, 30, 682-689.	4.9	103
341	The extramural metastasis might be categorized in lymph node staging for colorectal cancer. BMC Cancer, 2011, 11, 414.	1.1	7
342	Ratio of Metastatic To Resected Lymph Nodes Enhances To Predict Survival In Patients With Stage III Colorectal Cancer. Annals of Surgical Oncology, 2011, 18, 1568-1574.	0.7	39

#	Article	IF	Citations
343	Comparison of 6th and 7th AJCC TNM Staging Classification for Carcinoma of the Stomach in China. Annals of Surgical Oncology, 2011, 18, 1869-1876.	0.7	57
344	Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients. Medical Oncology, 2011, 28, 476-482.	1.2	6
345	A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China. Medical Oncology, 2011, 28, 268-273.	1.2	29
346	Expressions of hypoxia-inducible factor-1Î± and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features. Tumor Biology, 2011, 32, 159-166.	0.8	44
347	Prognostic analysis in node-negative gastric cancer patients in China. Tumor Biology, 2011, 32, 489-492.	0.8	14
348	Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. Tumor Biology, 2011, 32, 509-514.	0.8	33
349	Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumor Biology, 2011, 32, 697-705.	0.8	14
350	EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients. Clinical Cancer Research, 2011, 17, 382-390.	3.2	25
351	Phase 2 Study of Capecitabine and Irinotecan Combination Chemotherapy (Modified XELIRI Regimen) in Patients With Advanced Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 555-560.	0.6	17
352	HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World Journal of Gastroenterology, 2011, 17, 804.	1.4	33
353	Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World Journal of Gastroenterology, 2011, 17, 4779.	1.4	62
354	Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumor Biology, 2010, 31, 255-260.	0.8	53
355	Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. Tumor Biology, 2010, 31, 633-641.	0.8	49
356	Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer. Chemotherapy, 2010, 56, 94-100.	0.8	38
357	Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers, 2010, 15, 516-522.	0.9	199
358	Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. Journal of Translational Medicine, 2010, 8, 107.	1.8	21
359	DNA polymeraseÎ· protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. Journal of Translational Medicine, 2010, 8, 126.	1.8	53
360	Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers, 2010, 15, 243-248.	0.9	13

#	Article	IF	Citations
361	Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. International Journal of Biological Markers, 2009, 24, 258-264.	0.7	12
362	Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer: Experiences of 16 patients in single institute. Chinese-German Journal of Clinical Oncology, 2009, 8, 669-674.	0.1	0
363	Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. International Journal of Biological Markers, 2009, 24, 258-264.	0.7	12
364	The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Annals of Hematology, 2008, 87, 481-485.	0.8	44
365	Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer, 2008, 8, 115.	1.1	56
366	A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer. Chemotherapy, 2008, 54, 228-235.	0.8	24
367	High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer, 2007, 109, 1360-1364.	2.0	119
368	Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. Journal of Cell Biology, 2006, 175, 913-923.	2.3	345
369	OSW-1: a Natural Compound With Potent Anticancer Activity and a Novel Mechanism of Action. Journal of the National Cancer Institute, 2005, 97, 1781-1785.	3.0	91
370	Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Research, 2005, 65, 613-21.	0.4	506